Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Thymalfasin and Chemotherapy as Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT07780721Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Putian University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and thymosin alpha 1 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Hospital of Putian University. Primary endpoint: Pathologic Complete Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimabthymosin alpha 1
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07780721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780721.